Deallus white papers

The latest white papers from Deallus pharmaceutical and life science industry experts

Copay Accumulator Programs & Pharma

2021-05-12T11:56:49+01:00White Paper|

Dynamics between pharma and the market-based healthcare sector it serves have invariably been complex, with one of the biggest drivers of that complexity being effective management of patient demand and payer systems. The newest stratagem in this push and pull is the copay accumulator program, or CAP. We take a closer look at CAPs and how they might affect your brand in the near future.

Competitive Intelligence in an Agile World

2019-11-08T14:34:37+00:00White Paper|

Adapting competitive intelligence functions to an increasingly complex pharma landscape. This White Paper explores the concept of agile working for the pharma world, delving into the opportunities and challenges that arise for Competitive Intelligence teams and managers as working environments adapt to find success in a more dynamic, uncertain, and fast-paced environment.

Purchasing a Pipeline

2019-11-08T14:30:03+00:00White Paper|

Perils, pitfalls, and priorities in asset acquisition. In this White Paper, we will look at new and changing trends in pipeline acquisition, discuss difficulties inherent in the current marketplace, and offer worthwhile perspectives on pitfalls and opportunities based on our experience offering strategic guidance to pharmaceutical companies on a global scale.

The Three A’s of Launch Readiness

2020-02-12T11:48:23+00:00White Paper|

Drug launch failures happen more frequently than pharma companies care to admit. Anticipate, Adapt and Align - the three A’s of successful pharma launch strategy. To understand and implement them requires strategic vision, a holistic understanding of every vagary of the marketplace, and a forthright and ruthlessly honest assessment of both the product being launched and the competitive space it is meant to occupy.

Asia Market Entry

2020-06-22T08:14:43+01:00White Paper|

A continent of extremes, with great potential for growth. Geographically large, the assortment of cultures, people, disease profiles, and healthcare systems added to the juxtaposition of extreme wealth and extreme poverty, emphasises the many challenges faced by the pharmaceutical companies when thinking of entering Asia. Commercial success will depend on understanding the market dynamics by consolidating positioning within the market place with the requirements of each market.

Go to Top